DxGen and Precision Diabetes Partner to Launch New Diabetes POC Testing Analyzer in US
Posted on 24 Aug 2022
The diabetes point-of-care (POC) testing market continues to expand rapidly as the diabetic epidemic continues unabated. The global POC A1c testing market alone is estimated to be worth USD 500 million and is expected to grow to USD 680 million by 2023. Now, a strategic partnership to launch a fully-automatic POC analyzer in the US will provide a suite of diabetes tests in physician offices, smaller laboratories, outpatient clinics, and hospitals across the country, allowing clinicians to provide “real-time,” actionable test results to patients, rather than waiting for several days for standard laboratory test results.
DxGen Corp. (Seoul, Korea) and Precision Diabetes, Inc. (Raleigh, NC, USA) have entered in an exclusive agreement in the U.S. to launch Epithod AutoDx, a fully-automatic point-of-care (POC) analyzer that measures a comprehensive profile of diabetes tests. The initial test menu will begin with hemoglobin A1c, C-reactive protein, and urinary albumin, with additional diabetes tests to be added in the near future.
EpithodAutoDx is a small analyzer with a very user-friendly design and easy operation, making it uniquely suitable for point-of-care settings such as physician offices, smaller laboratories, outpatient clinics, and hospitals. By providing a suite of diabetes tests in these settings, clinicians will be able to provide “real-time,” actionable test results to patients, rather than waiting for several days for standard laboratory test results. TheEpithod AutoDx is well positioned to become a dominant player in the rapidly expanding diabetes POC testing market as the diabetes test menu continues to expand.
“By integrating Epithod AutoDx into our diabetes product portfolio, we are demonstrating our commitment to providing healthcare professionals access to important clinical diagnostics focused on early detection, prevention, and management of diabetes, prediabetes, and associated complications in point-of-care settings,” said Eric Button, Founder and CEO of Precision Diabetes, Inc.“As we continue to build the diabetes test menu, we believe we will have the most user-friendly and comprehensive POC diabetes test solution in the marketplace.”
“The COVID-19 pandemic has accelerated on-site testing worldwide, and Epithod AutoDx can measure multiple diabetes tests on one point-of-care analyzer, providing rapid results that enable clinicians to make faster clinical decisions,” said Jinwoo Lee of DxGen. “The strategic partnership in the United States between the two companies creates a powerful combination to help people with prediabetes and diabetes.”
Related links:
DxGen Corp
Precision Diabetes
